A new narrative review finds that SGLT2 inhibitors and incretin-based therapies preferentially reduce fat while lean tissue ...

Rising prevalence of diabetes, recent product approvals & product launches in the market, and recent advancement in incretin-based pharmacotherapies are the major factors driving the market for ...

Novel retatrutide worked in overweight, obese adults with and without type 2 diabetes ...

Dublin, April 10, 2025 (GLOBE NEWSWIRE) -- The "Incretin-based Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...

We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.

With incretin-based medications such as semaglutide and tirzepatide, obesity treatment has fundamentally changed in recent years. Intervention trials have shown weight reductions of up to 20%, and for ...

Incretin-based therapies have advanced treatment of type 2 diabetes but have been linked to pancreatitis and pancreatic cancer in some patients. Conflicting evidences for and against this suspicious ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative GPCR ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Incretin-based therapies are continuing to evolve with ...

Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — In this video, Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA, discusses notable updates across ...